1
|
Yang Z, Stein RA, Ngendahimana T, Pink M, Rajca S, Jeschke G, Eaton SS, Eaton GR, Mchaourab HS, Rajca A. Supramolecular Approach to Electron Paramagnetic Resonance Distance Measurement of Spin-Labeled Proteins. J Phys Chem B 2020; 124:3291-3299. [PMID: 32227839 DOI: 10.1021/acs.jpcb.0c00743] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
We demonstrate a host-guest molecular recognition approach to advance double electron-electron resonance (DEER) distance measurements of spin-labeled proteins. We synthesized an iodoacetamide derivative of 2,6-diazaadamantane nitroxide (DZD) spin label that could be doubly incorporated into T4 Lysozyme (T4L) by site-directed spin labeling with efficiency up to 50% per cysteine. The rigidity of the fused ring structure and absence of mobile methyl groups increase the spin echo dephasing time (Tm) at temperatures above 80 K. This enables DEER measurements of distances >4 nm in DZD-labeled T4L in glycerol/water at temperatures up to 150 K with increased sensitivity compared to that of a common spin label such as MTSL. Addition of β-cyclodextrin reduces the rotational correlation time of the label, slightly increases Tm, and most importantly, narrows (and slightly lengthens) the interspin distance distributions. The distance distributions are in good agreement with simulated distance distributions obtained by rotamer libraries. These results provide a foundation for developing supramolecular recognition to facilitate long-distance DEER measurements at near physiological temperatures.
Collapse
Affiliation(s)
- Zhimin Yang
- Department of Chemistry, University of Nebraska, Lincoln, Nebraska 68588-0304, United States
| | - Richard A Stein
- Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, Tennessee 37232, United States
| | - Thacien Ngendahimana
- Department of Chemistry and Biochemistry, University of Denver, Denver, Colorado 80208, United States
| | - Maren Pink
- IUMSC, Department of Chemistry, Indiana University, Bloomington, Indiana 47405-7102, United States
| | - Suchada Rajca
- Department of Chemistry, University of Nebraska, Lincoln, Nebraska 68588-0304, United States
| | - Gunnar Jeschke
- Department of Chemistry and Applied Biosciences, ETH Zürich, Vladimir-Prelog-Weg 2, CH-8093 Zürich, Switzerland
| | - Sandra S Eaton
- Department of Chemistry and Biochemistry, University of Denver, Denver, Colorado 80208, United States
| | - Gareth R Eaton
- Department of Chemistry and Biochemistry, University of Denver, Denver, Colorado 80208, United States
| | - Hassane S Mchaourab
- Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, Tennessee 37232, United States
| | - Andrzej Rajca
- Department of Chemistry, University of Nebraska, Lincoln, Nebraska 68588-0304, United States
| |
Collapse
|
2
|
Zuo Z, Chen M, Shao X, Qian X, Liu X, Zhou X, Xiang J, Deng P, Li Y, Jie H, Liu C, Cen X, Xie Y, Zhao Y. Design and biological evaluation of tetrahydropyridine derivatives as novel human GPR119 agonists. Bioorg Med Chem Lett 2019; 30:126855. [PMID: 31898998 DOI: 10.1016/j.bmcl.2019.126855] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2019] [Revised: 11/21/2019] [Accepted: 11/22/2019] [Indexed: 02/05/2023]
Abstract
A series of novel tetrahydropyridine derivatives were prepared and evaluated using cell-based measurements. Systematic optimization of general structure G-1 led to the identification of compound 35 (EC50 = 4.9 nM) and 37 (EC50 = 8.8 nM) with high GPR119 agonism activity and moderate clog P. Through single and long-term pharmacodynamic experiments, we found that compound35 showed a hypoglycemic effect and may have an effect on improving basal metabolic rate in DIO mice. Both in vitro and in vivo tests indicated that compound 35 was a potential potent GPR119 agonist in allusion to T2DM treatment.
Collapse
Affiliation(s)
- Zeping Zuo
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China
| | - Miaomiao Chen
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China
| | - Xiaoni Shao
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China
| | - Xinying Qian
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China
| | - Xiaocong Liu
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China
| | - Xia Zhou
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China
| | - Jiawei Xiang
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China
| | - Pengchi Deng
- Analytical &Testing Center, Sichuan University, Chengdu 610041, China
| | - Yan Li
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China
| | - Hui Jie
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China
| | - Chunqi Liu
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China
| | - Xiaobo Cen
- National Chengdu Center for Safety Evaluation of Drugs, State Key Lab of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China
| | - Yongmei Xie
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China.
| | - Yinglan Zhao
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China.
| |
Collapse
|
3
|
Nieto A, Fernández-Vega V, Spicer TP, Sturchler E, Adhikari P, Kennedy N, Mandat S, Chase P, Scampavia L, Bannister T, Hodder P, McDonald PH. Identification of Novel, Structurally Diverse, Small Molecule Modulators of GPR119. Assay Drug Dev Technol 2019; 16:278-288. [PMID: 30019946 DOI: 10.1089/adt.2018.849] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
GPR119 drug discovery efforts in the pharmaceutical industry for the treatment of type 2 diabetes mellitus (T2DM) and obesity, were initiated based on its restricted distribution in pancreas and GI tract, and its possible role in glucose homeostasis. While a number of lead series have emerged, the pharmacological endpoints they provide have not been clear. In particular, many lead series have demonstrated loss of efficacy and significant toxic side effects. Thus, we sought to identify novel, potent, positive modulators of GPR119. In this study, we have successfully developed and optimized a high-throughput screening strategy to identify GPR119 modulators using a live cell assay format that utilizes a cyclic nucleotide-gated channel as a biosensor for cAMP production. Our high-throughput screening (HTS) approach is unique to that of previous HTS approaches targeting this receptor, as changes in cAMP were measured both in the presence and absence of an EC10 of the endogenous ligand, oleoylethanolamide, enabling detection of both agonists and potential allosteric modulators in a single assay. From these efforts, we have identified positive modulators of GPR119 with similar as well as unique scaffolds compared to existing compounds and similar as well as unique signaling properties. Our compounds will not only serve as novel molecular probes to better understand GPR119 pleiotropic signaling and the underlying physiological consequences of receptor activation, but are also well-suited for translation as potential therapeutic agents.
Collapse
Affiliation(s)
- Ainhoa Nieto
- 1 Department of Molecular Medicine, The Scripps Research Institute , Jupiter, Florida
| | | | - Timothy P Spicer
- 1 Department of Molecular Medicine, The Scripps Research Institute , Jupiter, Florida
| | - Emmanuel Sturchler
- 1 Department of Molecular Medicine, The Scripps Research Institute , Jupiter, Florida
| | - Pramisha Adhikari
- 1 Department of Molecular Medicine, The Scripps Research Institute , Jupiter, Florida
| | - Nicole Kennedy
- 2 Department of Chemistry, The Scripps Research Institute , Jupiter, Florida
| | - Sean Mandat
- 1 Department of Molecular Medicine, The Scripps Research Institute , Jupiter, Florida
| | - Peter Chase
- 1 Department of Molecular Medicine, The Scripps Research Institute , Jupiter, Florida
| | - Louis Scampavia
- 1 Department of Molecular Medicine, The Scripps Research Institute , Jupiter, Florida
| | - Thomas Bannister
- 2 Department of Chemistry, The Scripps Research Institute , Jupiter, Florida
| | - Peter Hodder
- 1 Department of Molecular Medicine, The Scripps Research Institute , Jupiter, Florida
| | - Patricia H McDonald
- 1 Department of Molecular Medicine, The Scripps Research Institute , Jupiter, Florida
| |
Collapse
|
4
|
Wu J, Leas DA, Dong Y, Wang X, Ezell EL, Stack DE, Vennerstrom JL. Synthesis of 2-Azaadamantan-6-one: A Missing Isomer. ACS OMEGA 2018; 3:11362-11367. [PMID: 30288462 PMCID: PMC6166225 DOI: 10.1021/acsomega.8b01819] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/30/2018] [Accepted: 09/10/2018] [Indexed: 05/04/2023]
Abstract
2-Azaadamantan-6-one and its Boc and ethylene ketal derivatives were synthesized from 9-oxo endo-bicyclo[3.3.1]non-6-ene-3-carboxylic acid. Similarly, the Cbz, Boc, and ethylene ketal derivatives of 2-azaadamantan-4-one were synthesized from endo-bicyclo[3.3.1]non-6-ene-3-carboxylic acid. Key steps were Curtius rearrangements to form benzyl carbamates, followed by spontaneous intramolecular attack of the carbamate nitrogen on transient bromonium ion or epoxide intermediates to effect ring closure to azaadamantane intermediates. The reaction sequence leading to 2-azaadamantan-6-one is consistent with the formation of a transient tetracyclic keto aziridine intermediate.
Collapse
Affiliation(s)
- Jianbo Wu
- College
of Pharmacy and Eppley Institute for Research in Cancer, University of Nebraska Medical Center, Omaha, Nebraska 68198, United States
| | - Derek A. Leas
- College
of Pharmacy and Eppley Institute for Research in Cancer, University of Nebraska Medical Center, Omaha, Nebraska 68198, United States
| | - Yuxiang Dong
- College
of Pharmacy and Eppley Institute for Research in Cancer, University of Nebraska Medical Center, Omaha, Nebraska 68198, United States
| | - Xiaofang Wang
- College
of Pharmacy and Eppley Institute for Research in Cancer, University of Nebraska Medical Center, Omaha, Nebraska 68198, United States
| | - Edward L. Ezell
- College
of Pharmacy and Eppley Institute for Research in Cancer, University of Nebraska Medical Center, Omaha, Nebraska 68198, United States
| | - Douglas E. Stack
- Department
of Chemistry, University of Nebraska at
Omaha, Omaha, Nebraska 68182, United States
| | - Jonathan L. Vennerstrom
- College
of Pharmacy and Eppley Institute for Research in Cancer, University of Nebraska Medical Center, Omaha, Nebraska 68198, United States
- E-mail: (J.L.V.)
| |
Collapse
|
5
|
Design and synthesis of novel pyrimido[5,4-d]pyrimidine derivatives as GPR119 agonist for treatment of type 2 diabetes. Bioorg Med Chem 2018; 26:4080-4087. [DOI: 10.1016/j.bmc.2018.06.035] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2018] [Revised: 06/25/2018] [Accepted: 06/26/2018] [Indexed: 12/30/2022]
|
6
|
Taylor AP, Robinson RP, Fobian YM, Blakemore DC, Jones LH, Fadeyi O. Modern advances in heterocyclic chemistry in drug discovery. Org Biomol Chem 2018; 14:6611-37. [PMID: 27282396 DOI: 10.1039/c6ob00936k] [Citation(s) in RCA: 434] [Impact Index Per Article: 72.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
New advances in synthetic methodologies that allow rapid access to a wide variety of functionalized heterocyclic compounds are of critical importance to the medicinal chemist as it provides the ability to expand the available drug-like chemical space and drive more efficient delivery of drug discovery programs. Furthermore, the development of robust synthetic routes that can readily generate bulk quantities of a desired compound help to accelerate the drug development process. While established synthetic methodologies are commonly utilized during the course of a drug discovery program, the development of innovative heterocyclic syntheses that allow for different bond forming strategies are having a significant impact in the pharmaceutical industry. This review will focus on recent applications of new methodologies in C-H activation, photoredox chemistry, borrowing hydrogen catalysis, multicomponent reactions, regio- and stereoselective syntheses, as well as other new, innovative general syntheses for the formation and functionalization of heterocycles that have helped drive project delivery. Additionally, the importance and value of collaborations between industry and academia in shaping the development of innovative synthetic approaches to functionalized heterocycles that are of greatest interest to the pharmaceutical industry will be highlighted.
Collapse
Affiliation(s)
- Alexandria P Taylor
- Worldwide Medicinal Chemistry, Pfizer, Eastern Point Road, Groton, CT 06340, USA.
| | - Ralph P Robinson
- Worldwide Medicinal Chemistry, Pfizer, Eastern Point Road, Groton, CT 06340, USA.
| | - Yvette M Fobian
- Worldwide Medicinal Chemistry, Pfizer, Eastern Point Road, Groton, CT 06340, USA.
| | - David C Blakemore
- Worldwide Medicinal Chemistry, Pfizer, Eastern Point Road, Groton, CT 06340, USA.
| | - Lyn H Jones
- Worldwide Medicinal Chemistry, Pfizer, 610 Main Street, Cambridge, MA 02139, USA
| | - Olugbeminiyi Fadeyi
- Worldwide Medicinal Chemistry, Pfizer, Eastern Point Road, Groton, CT 06340, USA.
| |
Collapse
|
7
|
Hou T, Ruan H, Wang G, Luo J. 2,4,4,8,8-Pentanitro-2-Azaadamantane: A High-Density Energetic Compound. European J Org Chem 2017. [DOI: 10.1002/ejoc.201701403] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Affiliation(s)
- Tianjiao Hou
- School of Chemical Engineering; Nanjing University of Science and Technology; 210094 Nanjing China
| | - Hongwei Ruan
- School of Chemical Engineering; Nanjing University of Science and Technology; 210094 Nanjing China
| | - Guixiang Wang
- School of Chemical Engineering; Nanjing University of Science and Technology; 210094 Nanjing China
| | - Jun Luo
- School of Chemical Engineering; Nanjing University of Science and Technology; 210094 Nanjing China
| |
Collapse
|
8
|
Synthesis and biological evaluation of pyrimidine derivatives with diverse azabicyclic ether/amine as novel GPR119 agonist. Bioorg Med Chem Lett 2017; 27:2515-2519. [PMID: 28408218 DOI: 10.1016/j.bmcl.2017.03.092] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2017] [Revised: 03/19/2017] [Accepted: 03/31/2017] [Indexed: 11/23/2022]
Abstract
A class of novel pyrimidine derivatives bearing diverse conformationally restricted azabicyclic ether/amine were designed, synthesized and evaluated for their GPR119 agonist activities against type 2 diabetes. Most compounds exhibited superior hEC50 values to endogenous lipid oleoylethanolamide (OEA). Analogs with 2-fluoro substitution in the aryl ring showed more potent GPR119 activation than those without fluorine. Especially compound 27m synthesized from endo-azabicyclic alcohol was observed to have the best EC50 value (1.2nM) and quite good agonistic activity (112.2% max) as a full agonist.
Collapse
|
9
|
Hou T, Zhang J, Wang C, Luo J. A facile method to construct a 2,4,9-triazaadamantane skeleton and synthesize nitramine derivatives. Org Chem Front 2017. [DOI: 10.1039/c7qo00357a] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
An unusual protocol for a “one-pot” three-step reaction to build a 2,4,9-triazaadamantane skeleton from triallylcarbinol was developed.
Collapse
Affiliation(s)
- Tianjiao Hou
- School of Chemical Engineering
- Nanjing University of Science and Technology
- Nanjing 210094
- China
| | - Jian Zhang
- School of Chemical Engineering
- Nanjing University of Science and Technology
- Nanjing 210094
- China
| | - Chenjiao Wang
- School of Chemical Engineering
- Nanjing University of Science and Technology
- Nanjing 210094
- China
| | - Jun Luo
- School of Chemical Engineering
- Nanjing University of Science and Technology
- Nanjing 210094
- China
| |
Collapse
|
10
|
Recent Advances of Microfluidics Technologies in the Field of Medicinal Chemistry. ANNUAL REPORTS IN MEDICINAL CHEMISTRY 2017. [DOI: 10.1016/bs.armc.2017.09.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
11
|
Fang Y, Yang Z, Gundeti S, Lee J, Park H. Novel 5-nitropyrimidine derivatives bearing endo-azabicyclic alcohols/amines as potent GPR119 agonists. Bioorg Med Chem 2017; 25:254-260. [DOI: 10.1016/j.bmc.2016.10.030] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2016] [Revised: 10/24/2016] [Accepted: 10/26/2016] [Indexed: 10/20/2022]
|
12
|
Ritter K, Buning C, Halland N, Pöverlein C, Schwink L. G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges. J Med Chem 2015; 59:3579-92. [PMID: 26512410 DOI: 10.1021/acs.jmedchem.5b01198] [Citation(s) in RCA: 86] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
In this Perspective, recent advances and challenges in the development of GPR119 agonists as new oral antidiabetic drugs will be discussed. Such agonists are expected to exhibit a low risk to induce hypoglycemia as well as to have a beneficial impact on body weight. Many pharmaceutical companies have been active in the search for GPR119 agonists, making it a highly competitive area in the industrial environment. Several GPR119 agonists have been entered into clinical studies, but many have failed either in phase I or II and none has progressed beyond phase II. Herein we describe the strategies chosen by the different medicinal chemistry teams in academia and the pharmaceutical industry to improve potency, physicochemical properties, pharmacokinetics, and the safety profile of GPR119 agonists in the discovery phase in order to improve the odds for successful development.
Collapse
Affiliation(s)
- Kurt Ritter
- Sanofi-Aventis Deutschland GmbH , Building G838, Industriepark Hoechst, 65926 Frankfurt, Germany
| | - Christian Buning
- Sanofi-Aventis Deutschland GmbH , Building G838, Industriepark Hoechst, 65926 Frankfurt, Germany
| | - Nis Halland
- Sanofi-Aventis Deutschland GmbH , Building G838, Industriepark Hoechst, 65926 Frankfurt, Germany
| | - Christoph Pöverlein
- Sanofi-Aventis Deutschland GmbH , Building G838, Industriepark Hoechst, 65926 Frankfurt, Germany
| | - Lothar Schwink
- Sanofi-Aventis Deutschland GmbH , Building G838, Industriepark Hoechst, 65926 Frankfurt, Germany
| |
Collapse
|
13
|
Dai X, Stamford A, Liu H, Neustadt B, Hao J, Kowalski T, Hawes B, Xu X, Baker H, O’Neill K, Woods M, Tang H, Greenlee W. Discovery of the oxazabicyclo[3.3.1]nonane derivatives as potent and orally active GPR119 agonists. Bioorg Med Chem Lett 2015; 25:5291-4. [DOI: 10.1016/j.bmcl.2015.09.047] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2015] [Accepted: 09/18/2015] [Indexed: 02/07/2023]
|
14
|
Singh A, Falabella J, LaPorte TL, Goswami A. Enzymatic Process for N-Substituted (3S)- and (3R)-3-Hydroxypyrrolidin-2-ones. Org Process Res Dev 2015. [DOI: 10.1021/acs.oprd.5b00084] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Affiliation(s)
- Amarjit Singh
- Chemical Development, Bristol-Myers Squibb, One Squibb Drive, New Brunswick, New Jersey 08903, United States
| | - James Falabella
- Chemical Development, Bristol-Myers Squibb, One Squibb Drive, New Brunswick, New Jersey 08903, United States
| | - Thomas L LaPorte
- Chemical Development, Bristol-Myers Squibb, One Squibb Drive, New Brunswick, New Jersey 08903, United States
| | - Animesh Goswami
- Chemical Development, Bristol-Myers Squibb, One Squibb Drive, New Brunswick, New Jersey 08903, United States
| |
Collapse
|
15
|
Scott JS, Bowker SS, Brocklehurst KJ, Brown HS, Clarke DS, Easter A, Ertan A, Goldberg K, Hudson JA, Kavanagh S, Laber D, Leach AG, MacFaul PA, Martin EA, McKerrecher D, Schofield P, Svensson PH, Teague J. Circumventing Seizure Activity in a Series of G Protein Coupled Receptor 119 (GPR119) Agonists. J Med Chem 2014; 57:8984-98. [DOI: 10.1021/jm5011012] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Affiliation(s)
- James S. Scott
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Suzanne S. Bowker
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Katy J. Brocklehurst
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Hayley S. Brown
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - David S. Clarke
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Alison Easter
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Anne Ertan
- Pharmaceutical Development, AstraZeneca R&D, S-151 85 Södertälje, Sweden
| | - Kristin Goldberg
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Julian A. Hudson
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Stefan Kavanagh
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - David Laber
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Andrew G. Leach
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Philip A. MacFaul
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Elizabeth A. Martin
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Darren McKerrecher
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Paul Schofield
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| | - Per H. Svensson
- Pharmaceutical Development, AstraZeneca R&D, S-151 85 Södertälje, Sweden
| | - Joanne Teague
- Innovative
Medicines Unit, AstraZeneca Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K
| |
Collapse
|
16
|
Sagong HY, Bauman J, Patel D, Das K, Arnold E, LaVoie EJ. Phenyl substituted 4-hydroxypyridazin-3(2H)-ones and 5-hydroxypyrimidin-4(3H)-ones: inhibitors of influenza A endonuclease. J Med Chem 2014; 57:8086-98. [PMID: 25225968 PMCID: PMC4191602 DOI: 10.1021/jm500958x] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Seasonal and pandemic influenza outbreaks remain a major human health problem. Inhibition of the endonuclease activity of influenza RNA-dependent RNA polymerase is attractive for the development of new agents for the treatment of influenza infection. Our earlier studies identified a series of 5- and 6-phenyl substituted 3-hydroxypyridin-2(1H)-ones that were effective inhibitors of influenza endonuclease. These agents identified as bimetal chelating ligands binding to the active site of the enzyme. In the present study, several aza analogues of these phenyl substituted 3-hydroxypyridin-2(1H)-one compounds were synthesized and evaluated for their ability to inhibit the endonuclease activity. In contrast to the 4-aza analogue of 6-(4-fluorophenyl)-3-hydroxypyridin-2(1H)-one, the 5-aza analogue (5-hydroxy-2-(4-fluorophenyl)pyrimidin-4(3H)-one) did exhibit significant activity as an endonuclease inhibitor. The 6-aza analogue of 5-(4-fluorophenyl)-3-hydroxypyridin-2(1H)-one (6-(4-fluorophenyl)-4-hydroxypyridazin-3(2H)-one) also retained modest activity as an inhibitor. Several varied 6-phenyl-4-hydroxypyridazin-3(2H)-ones and 2-phenyl-5-hydroxypyrimidin-4(3H)-ones were synthesized and evaluated as endonuclease inhibitors. The SAR observed for these aza analogues are consistent with those previously observed with various phenyl substituted 3-hydroxypyridin-2(1H)-ones.
Collapse
Affiliation(s)
- Hye Yeon Sagong
- Department
of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854-8020, United States
| | - Joseph
D. Bauman
- Center
for Advanced Biotechnology and Medicine and Department of Chemistry
and Chemical Biology, Rutgers University, Piscataway, New Jersey 08854-5627, United States
| | - Disha Patel
- Center
for Advanced Biotechnology and Medicine and Department of Chemistry
and Chemical Biology, Rutgers University, Piscataway, New Jersey 08854-5627, United States
| | - Kalyan Das
- Center
for Advanced Biotechnology and Medicine and Department of Chemistry
and Chemical Biology, Rutgers University, Piscataway, New Jersey 08854-5627, United States
| | - Eddy Arnold
- Center
for Advanced Biotechnology and Medicine and Department of Chemistry
and Chemical Biology, Rutgers University, Piscataway, New Jersey 08854-5627, United States
| | - Edmond J. LaVoie
- Department
of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854-8020, United States,Phone: +1 (848) 445 2674. Fax: +1 (732) 445 6312.
| |
Collapse
|
17
|
Ye XY, Morales CL, Wang Y, Rossi KA, Malmstrom SE, Abousleiman M, Sereda L, Apedo A, Robl JA, Miller KJ, Krupinski J, Wacker DA. Synthesis and structure–activity relationship of dihydrobenzofuran derivatives as novel human GPR119 agonists. Bioorg Med Chem Lett 2014; 24:2539-45. [DOI: 10.1016/j.bmcl.2014.03.096] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2014] [Revised: 03/26/2014] [Accepted: 03/28/2014] [Indexed: 12/11/2022]
|
18
|
Discovery of pyrazolo[3,4-d]pyrimidine derivatives as GPR119 agonists. Bioorg Med Chem Lett 2014; 24:949-53. [DOI: 10.1016/j.bmcl.2013.12.063] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2013] [Revised: 12/13/2013] [Accepted: 12/16/2013] [Indexed: 11/24/2022]
|
19
|
Hopkins AL, Keserü GM, Leeson PD, Rees DC, Reynolds CH. The role of ligand efficiency metrics in drug discovery. Nat Rev Drug Discov 2014; 13:105-21. [DOI: 10.1038/nrd4163] [Citation(s) in RCA: 706] [Impact Index Per Article: 70.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
20
|
Shibuya K, Koshizawa T, Hosoi H, Watanabe G, Morimoto T, Ohgiya T. A Practical Synthesis of (4-(Spiro[chromane-2,4'-piperidin]-6-yl)phenyl)methanol as a Key Intermediate of Novel GPR119 Agonist. HETEROCYCLES 2014. [DOI: 10.3987/com-14-13012] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
21
|
Targeting GPR119 for the Potential Treatment of Type 2 Diabetes Mellitus. PROGRESS IN MOLECULAR BIOLOGY AND TRANSLATIONAL SCIENCE 2014; 121:95-131. [DOI: 10.1016/b978-0-12-800101-1.00004-1] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
22
|
Kang SU. GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119. Drug Discov Today 2013; 18:1309-15. [PMID: 24060477 DOI: 10.1016/j.drudis.2013.09.011] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2013] [Revised: 08/20/2013] [Accepted: 09/13/2013] [Indexed: 01/08/2023]
Abstract
Ever since its advent as a promising therapeutic target for type 2 diabetes mellitus (T2DM), G-protein-coupled receptor 119 (GPR119) has received much interest from the pharmaceutical industry. This interest peaked in June 2010, when Sanofi-Aventis agreed to pay Metabolex (Cymabay Therapeutics) US$375 million for MBX-2982, which was a representative orally active GPR119 agonist. However, Sanofi-Aventis opted to terminate the deal in May 2011 and another leading GPR119 agonist, GSK1292263, had a loss of efficacy during its clinical trial. In this review, I discuss the pros and cons of GPR119 through a strengths, weaknesses, opportunities, and threats (SWOT) analysis and propose development strategies for the eventual success of a GPR119 agonist development program.
Collapse
Affiliation(s)
- Sang-Uk Kang
- Kosin University, Department of Life Sciences, 149-1, Dongsam-dong, Yeongdogu, Busan, South Korea.
| |
Collapse
|
23
|
Glasnov TN. Highlights from the Flow Chemistry Literature 2013 (Part 1). J Flow Chem 2013. [DOI: 10.1556/jfc-d-13-00008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
24
|
Scott JS, Brocklehurst KJ, Brown HS, Clarke DS, Coe H, Groombridge SD, Laber D, MacFaul PA, McKerrecher D, Schofield P. Conformational restriction in a series of GPR119 agonists: differences in pharmacology between mouse and human. Bioorg Med Chem Lett 2013; 23:3175-9. [PMID: 23628336 DOI: 10.1016/j.bmcl.2013.04.006] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2013] [Revised: 03/28/2013] [Accepted: 04/02/2013] [Indexed: 02/07/2023]
Abstract
A series of conformationally restricted GPR119 agonists were prepared based around a 3,8-diazabicyclo[3.2.1]octane scaffold. Examples were found to have markedly different pharmacology in mouse and human despite similar levels of binding to the receptor. This highlights the large effects on GPCR phamacology that can result from small structural changes in the ligand, together with inter-species differences between receptors.
Collapse
Affiliation(s)
- James S Scott
- Cardiovascular & Gastrointestinal Innovative Medicines Unit, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Iwabuchi Y, Sasano Y, Nishiyama T, Tomizawa M, Shibuya M. C–H MODIFICATION OF 2-AZAADAMANTANE: SYNTHESIS OF C5-FUNCTIONALIZED AZADOS FOR ADVANCED USE. HETEROCYCLES 2013. [DOI: 10.3987/com-13-12804] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|